Anna Sparatore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8203197/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-inflammatory, but not osteoprotective, effect of the TRAF6/CD40 inhibitor 6877002 in rodent models of local and systemic osteolysis. Biochemical Pharmacology, 2022, 195, 114869.	4.4	2
2	MZe786, a hydrogen sulfide-releasing aspirin prevents preeclampsia in heme oxygenase-1 haplodeficient pregnancy under high soluble flt-1 environment. Redox Biology, 2021, 38, 101768.	9.0	14
3	Hydrogen sulfide releasing molecule MZe786 inhibits soluble Flt-1 and prevents preeclampsia in a refined RUPP mouse model. Redox Biology, 2021, 38, 101814.	9.0	20
4	Superior Properties of N-Acetylcysteine Ethyl Ester over N-Acetyl Cysteine to Prevent Retinal Pigment Epithelial Cells Oxidative Damage. International Journal of Molecular Sciences, 2021, 22, 600.	4.1	11
5	Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity inÂvitro and inÂvivo. European Journal of Medicinal Chemistry, 2021, 222, 113562.	5.5	9
6	Design, Synthesis and In Vitro Investigation of Novel Basic Celastrol Carboxamides as Bio-Inspired Leishmanicidal Agents Endowed with Inhibitory Activity against Leishmania Hsp90. Biomolecules, 2021, 11, 56.	4.0	14
7	MZe786 Rescues Cardiac Mitochondrial Activity in High sFlt-1 and Low HO-1 Environment. Antioxidants, 2020, 9, 598.	5.1	12
8	Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity. Pharmaceuticals, 2020, 13, 339.	3.8	7
9	Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 2020, 488, 27-39.	7.2	15
10	Novel Hydrophilic Riminophenazines as Potent Antiprotozoal Agents. ChemMedChem, 2019, 14, 1940-1949.	3.2	7
11	Benzimidazole derivatives endowed with potent antileishmanial activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 210-226.	5.2	33
12	The new H ₂ S-releasing compound ACS94 exerts protective effects through the modulation of thiol homoeostasis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1392-1404.	5.2	10
13	Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 337-344.	5.2	8
14	New sulfurated derivatives of cinnamic acids and rosmaricine as inhibitors of STAT3 and NF-κB transcription factors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1012-1028.	5.2	8
15	In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial. Molecules, 2017, 22, 2102.	3.8	12
16	Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest. Arkivoc, 2017, 2017, 235-250.	0.5	2
17	Synthesis and Antiplasmodial Activity of Novel Chloroquine Analogues with Bulky Basic Side Chains. ChemMedChem, 2015, 10, 1570-1583.	3.2	15
18	Multitarget Therapeutic Leads for Alzheimer's Disease: Quinolizidinyl Derivatives of Bi―and Tricyclic Systems as Dual Inhibitors of Cholinesterases and βâ€Amyloid (Aβ) Aggregation. ChemMedChem, 2015, 10, 1040-1053.	3.2	40

#	Article	IF	CITATIONS
19	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. Bioorganic and Medicinal Chemistry, 2015, 23, 7024-7034.	3.0	17
20	Clofazimine analogs with antileishmanial and antiplasmodial activity. Bioorganic and Medicinal Chemistry, 2015, 23, 55-65.	3.0	20
21	Hydrogen Sulfide Inhibits Human Platelet Aggregation In Vitro in Part by Interfering Gap Junction Channels: Effects of ACS14, a Hydrogen Sulfide-releasing Aspirin. Heart Lung and Circulation, 2015, 24, 77-85.	0.4	34
22	Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines. Bioorganic and Medicinal Chemistry, 2014, 22, 6837-6845.	3.0	7
23	Synthesis and evaluation of the antiplasmodial activity of novel indeno[2,1-c]quinoline derivatives. Bioorganic and Medicinal Chemistry, 2014, 22, 5757-5765.	3.0	12
24	Anethole dithiolethione lowers the homocysteine and raises the glutathone levels in solid tissues and plasma of rats: A novel non-vitamin homocysteine-lowering agent. Biochemical Pharmacology, 2014, 89, 246-254.	4.4	18
25	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents. Bioorganic and Medicinal Chemistry, 2014, 22, 4893-4909.	3.0	61
26	Hydrogen Sulfide Releasing Aspirin, ACS14, Attenuates High Glucose-Induced Increased Methylglyoxal and Oxidative Stress in Cultured Vascular Smooth Muscle Cells. PLoS ONE, 2014, 9, e97315.	2.5	20
27	Role of Paraoxonase-1 in the Protection of Hydrogen Sulfide-Donating Sildenafil (ACS6) Against Homocysteine-Induced Neurotoxicity. Journal of Molecular Neuroscience, 2013, 50, 70-77.	2.3	16
28	Therapeutic Effect of Hydrogen Sulfide-Releasing L-Dopa Derivative ACS84 on 6-OHDA-Induced Parkinson's Disease Rat Model. PLoS ONE, 2013, 8, e60200.	2.5	56
29	Dithiolethiones Inhibit NF-κB Activity via Covalent Modification in Human Estrogen Receptor–Negative Breast Cancer. Cancer Research, 2012, 72, 2394-2404.	0.9	39
30	Hydrogen Sulfide–Releasing Aspirin Derivative ACS14 Exerts Strong Antithrombotic Effects In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2884-2891.	2.4	47
31	Glutamate oxidative injury to RGC-5 cells in culture is necrostatin sensitive and blunted by a hydrogen sulfide (H2S)-releasing derivative of aspirin (ACS14). Neurochemistry International, 2012, 60, 365-378.	3.8	36
32	Synthesis and antiplasmodial activity of new heteroaryl derivatives of 7-chloro-4-aminoquinoline. Bioorganic and Medicinal Chemistry, 2012, 20, 5965-5979.	3.0	27
33	Synthesis and comparison of antiplasmodial activity of (+), (â^') and racemic 7-chloro-4-(N-lupinyl)aminoquinoline. Bioorganic and Medicinal Chemistry, 2012, 20, 5980-5985.	3.0	11
34	Effect of S-aspirin, a novel hydrogen-sulfide-releasing aspirin (ACS14), on atherosclerosis in apoE-deficient mice. European Journal of Pharmacology, 2012, 697, 106-116.	3.5	42
35	Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity. Journal of Cellular Physiology, 2012, 227, 3389-3396.	4.1	24
36	Hydrogen sulphideâ€releasing diclofenac derivatives inhibit breast cancerâ€induced osteoclastogenesis <i>in vitro</i> and prevent osteolysis <i>ex vivo</i> . British Journal of Pharmacology, 2012, 165, 1914-1925.	5.4	34

ANNA SPARATORE

#	Article	IF	CITATIONS
37	H(2)S-Releasing Aspirin Protects against Aspirin-Induced Gastric Injury via Reducing Oxidative Stress. PLoS ONE, 2012, 7, e46301.	2.5	39
38	Therapeutic potential of new hydrogen sulfide-releasing hybrids. Expert Review of Clinical Pharmacology, 2011, 4, 109-121.	3.1	73
39	ACS84, a novel hydrogen sulfide-releasing compound, protects against amyloid β-induced cell cytotoxicity. Neurochemistry International, 2011, 58, 591-598.	3.8	23
40	H2S releasing aspirin protects amyloid beta induced cell toxicity in BV-2 microglial cells. Neuroscience, 2011, 193, 80-88.	2.3	20
41	S-diclofenac Protects against Doxorubicin-Induced Cardiomyopathy in Mice via Ameliorating Cardiac Gap Junction Remodeling. PLoS ONE, 2011, 6, e26441.	2.5	28
42	Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease. European Journal of Medicinal Chemistry, 2011, 46, 2170-2184.	5.5	56
43	Efficacy of Novel Acridine Derivatives in the Inhibition of hPrP90-231 Prion Protein Fragment Toxicity. Neurotoxicity Research, 2011, 19, 556-574.	2.7	31
44	ACS6, a Hydrogen sulfide-donating derivative of sildenafil, inhibits homocysteine-induced apoptosis by preservation of mitochondrial function. Medical Gas Research, 2011, 1, 20.	2.3	26
45	Reply to Savolainen: High Toxicity of Hydrogen Sulfide by the Inhibition of Mitochondrial Respiration. Journal of Biological Chemistry, 2010, 285, le10.	3.4	Ο
46	New aryldithiolethione derivatives as potent histone deacetylase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4187-4194.	3.0	17
47	Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats. European Journal of Pharmacology, 2010, 648, 139-145.	3.5	45
48	Modulation of thiol homeostasis induced by H2S-releasing aspirin. Free Radical Biology and Medicine, 2010, 48, 1263-1272.	2.9	47
49	Hydrogen sulfideâ€releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Clia, 2010, 58, 103-113.	4.9	92
50	Synthesis, antimalarial activity, and cellular toxicity of new arylpyrrolylaminoquinolines. Bioorganic and Medicinal Chemistry, 2010, 18, 6625-6633.	3.0	10
51	ACS67, a Hydrogen Sulfide–Releasing Derivative of Latanoprost Acid, Attenuates Retinal Ischemia and Oxidative Stress to RGC-5 Cells in Culture. , 2010, 51, 284.		61
52	Effects of Hydrogen Sulfide-releasing l-DOPA Derivatives on Clial Activation. Journal of Biological Chemistry, 2010, 285, 17318-17328.	3.4	99
53	Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer, 2010, 68, 154-160.	2.0	35
54	Novel Quinolizidinyl Derivatives as Antiarrhythmic Agents: 2. Further Investigation. Journal of Medicinal Chemistry, 2010, 53, 4668-4677.	6.4	12

ANNA SPARATORE

#	Article	IF	CITATIONS
55	Novel Antimalarial Aminoquinolines: Heme Binding and Effects on Normal or Plasmodium falciparum -Parasitized Human Erythrocytes. Antimicrobial Agents and Chemotherapy, 2009, 53, 4339-4344.	3.2	23
56	Novel Dithiolethione-Modified Nonsteroidal Anti-Inflammatory Drugs in Human Hepatoma HepG2 and Colon LS180 Cells. Clinical Cancer Research, 2009, 15, 1964-1972.	7.0	28
57	Pharmacological profile of a novel H2S-releasing aspirin. Free Radical Biology and Medicine, 2009, 46, 586-592.	2.9	121
58	Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene, 2009, 28, 3837-3846.	5.9	43
59	Effect of hydrogen sulphideâ€donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats. BJU International, 2009, 103, 1522-1529.	2.5	84
60	New prostaglandin derivative for glaucoma treatment. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1639-1642.	2.2	46
61	Atovaquoneâ€&tatine "Doubleâ€Drugs―with High Antiplasmodial Activity. ChemMedChem, 2008, 3, 418-42	03.2	16
62	Novel amodiaquine congeners as potent antimalarial agents. Bioorganic and Medicinal Chemistry, 2008, 16, 6813-6823.	3.0	43
63	Antimicrobial and cytotoxic arylazoenamines. Part III: Antiviral activity of selected classes of arylazoenamines. Bioorganic and Medicinal Chemistry, 2008, 16, 8447-8465.	3.0	23
64	New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1893-1897.	2.2	33
65	Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3737-3740.	2.2	44
66	H ₂ Sâ€donating sildenafil (ACS6) inhibits superoxide formation and gp91 ^{phox} expression in arterial endothelial cells: role of protein kinases A and G. British Journal of Pharmacology, 2008, 155, 984-994.	5.4	98
67	The hydrogen sulphideâ€releasing derivative of diclofenac protects against ischaemia–reperfusion injury in the isolated rabbit heart. British Journal of Pharmacology, 2008, 153, 100-109.	5.4	71
68	Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. European Journal of Pharmacology, 2008, 594, 1-8.	3.5	76
69	New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. Journal of Cellular and Molecular Medicine, 2008, 12, 2457-2466.	3.6	26
70	Exogenous Hydrogen Sulfide Inhibits Superoxide Formation, NOX-1 Expression and Rac ₁ Activity in Human Vascular Smooth Muscle Cells. Journal of Vascular Research, 2008, 45, 521-528.	1.4	101
71	Targeting the Plasmepsin 4 Orthologs of Plasmodium sp. with "Double Drug" Inhibitors. Protein and Peptide Letters, 2008, 15, 868-873.	0.9	8
72	TREATMENT WITH H2S-RELEASING DICLOFENAC PROTECTS MICE AGAINST ACUTE PANCREATITIS-ASSOCIATED LUNG INJURY. Shock, 2008, 29, 84-88.	2.1	50

ANNA SPARATORE

#	Article	IF	CITATIONS
73	Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. British Journal of Pharmacology, 2007, 151, 142-151.	5.4	71
74	Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radical Biology and Medicine, 2007, 42, 706-719.	2.9	301
75	Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat. European Journal of Pharmacology, 2007, 569, 149-154.	3.5	60
76	High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 7440-7449.	6.4	31
77	[4-(2H-1,2,3-Benzotriazol-2-yl)phenoxy]alkanoic Acids as Agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Chemistry and Biodiversity, 2006, 3, 385-395.	2.1	9
78	4-Aminoquinoline quinolizidinyl- and quinolizidinylalkyl-derivatives with antimalarial activity. Bioorganic and Medicinal Chemistry, 2005, 13, 5338-5345.	3.0	54
79	Epimerization of Lupinine to Epilupinine andvice versa. Reexamination of the Structures of Lupinal and Epilupinal. Helvetica Chimica Acta, 2005, 88, 245-251.	1.6	8
80	1-(Arylalkyl)quinolizidine Derivatives and Thio-Isosteric Analogues as Ligands for Sigma Receptors. Helvetica Chimica Acta, 2004, 87, 580-591.	1.6	9
81	Plasmepsin II inhibition and antiplasmodial activity of Primaquine–Statine `double-drugs'. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2931-2934.	2.2	38
82	N-Homolupinanoyl and N-(ω-lupinylthio)alkanoyl derivatives of some tricyclic systems as ligands for muscarinic M1 and M2 receptor subtypes. Il Farmaco, 2003, 58, 669-676.	0.9	5
83	Novel Sigma Binding Site Ligands as Inhibitors of Cell Proliferation in Breast Cancer. Oncology Research, 2003, 13, 455-461.	1.5	15
84	2-(4-R-Phenoxy/phenylthio)alkanoic esters of l-lupinine. Il Farmaco, 2001, 56, 169-174.	0.9	4
85	Quinolizidinyl derivatives of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one as ligands for muscarinic receptors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3031-3034.	2.2	20
86	Quinolizidinyl derivatives of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid and 1-homolupinanoyl benzimidazolones as ligands for 5-HT3 and 5-HT4 receptors. Il Farmaco, 1999, 54, 248-254.	0.9	6
87	2-{4-[3-(4-Aryl/heteroaryl-1-piperazinyl)propoxy]phenyl}-2H-benzotriazoles and their N-oxides as ligands for serotonin and dopamine receptors. Il Farmaco, 1999, 54, 402-410.	0.9	4
88	Synthesis and pharmacological investigation of 9-methyl-1,2,3,4,6,7,12,12b-octahydro-7-oxo-indolo[2,3-a]quinolizine. Il Farmaco, 1999, 54, 479-485.	0.9	5
89	Synthesis and preliminary pharmacological investigation of some 2-[4-(dialkylaminoalkoxy) phenyl] benzotriazoles and their N-oxides. Il Farmaco, 1998, 53, 102-112.	0.9	11
90	Detection and mass spectrometric characterization of the major urinary and fecal metabolites of 9-methyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]-quinolizine in the rat. European Journal of Drug Metabolism and Pharmacokinetics, 1995, 20, 135-144.	1.6	1

#	Article	IF	CITATIONS
91	Field desorption mass spectrometry, fast atom bombardment mass spectrometry and fast atom bombardment tandem mass spectrometry of echinacoside, the main caffeoyl-glycoside fromEchinacea angustifolia roots (Asteraceae). Organic Mass Spectrometry, 1991, 26, 951-955.	1.3	3
92	Effects of some rigid analogues of imipramine and amitriptyline on the uptake of noradrenaline, serotonin and choline in rat brain synaptosomes. Pharmacological Research Communications, 1982, 14, 257-265.	0.2	2